Skip to content

A randomized, double-blind, placebo-controlled clinical study for the efficacy and safety of modified Wenjing decoction formula granules

A randomized, double-blind, placebo-controlled clinical study for the efficacy and safety of modified Wenjing decoction formula granules

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026567
Enrollment
Unknown
Registered
2019-10-14
Start date
2019-10-21
Completion date
Unknown
Last updated
2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menstrual disease

Interventions

Treatment group (1):Formula granule of adding and reducing temperature and meridian decoction (single decoction)
Treatment group (2):Formula granule of adding and reducing temperature and meridian decoction (fried together)
Control group:Formula granule simulator for adding and reducing temperature and meridian decoction

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. It accords with the diagnostic criteria of menstrual diseases; 2. Aged 18-35 years old, more than 1 year after enlistment; 3. Volunteering to participate in this study and signing an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Organic injury of reproductive organs (endometriosis, adenomyosis, endometrial polyps, polycystic ovary syndrome, pelvic inflammatory disease, genital tumor, infection, early ovarian insufficiency, etc.) affected menstruation; 2. Women in special physiological period such as pregnancy and lactation; 3. Using IUD, taking contraceptive and so on to affect menstruation; 4. Patients with heart, brain, liver, kidney, thyroid disease, disease and other serious gynecological diseases; 5. Those who participated in other clinical trials in the past 3 months; 6. Those who are known to be allergic to the drug used in this experiment.

Design outcomes

Primary

MeasureTime frame
Menstrual irregularity score;Dysmenorrhea degree score;

Secondary

MeasureTime frame
Anxiety and depression state score;Physical status score;

Countries

China

Contacts

Public ContactYongqi Dou

Chinese PLA General Hospital

dyqi_301@yeah.com+86 13910335981

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026